ReviewNature reviews. Endocrinology2018
Follow-up of differentiated thyroid cancer - what should (and what should not) be done.
Review in Nature reviews. Endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mutations of the DICER1 gene among children and adolescents with thyroid cancer: a systematic review.Pediatric research · 2026Pooled it
- Deciphering functional intra-tumoral heterogeneity in BRAFOncogene · 2026Article
- Thyroid carcinoma follow-up: tertiary to primary care transition in Portugal.Endocrine connections · 2026Article
- Causal Associations of Heparin-Binding Growth and Differentiation Factors With Thyroid Cancer: A Two-Sample Mendelian Randomization Study.International journal of endocrinology · 2026Article
- PROS1-MERTK Axis Drives Tumor Microenvironment Crosstalk and Progression in Papillary Thyroid Microcarcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The Relationship Between Serum Levels of Thyroglobulin Antibody and the Risk of Recurrence in Patients With Differentiated Thyroid Cancer.Cancer reports (Hoboken, N.J.) · 2025Article
- Risk of Cancer Recurrence Exerts the Strongest Influence on Choice Between Active Surveillance and Thyroid Surgery as Initial Treatment for Low-Risk Thyroid Cancer: Results of a Discrete Choice Experiment.World journal of surgery · 2025Article
- Article
- Serum microRNA-146a-5p and microRNA-221-3p as potential clinical biomarkers for papillary thyroid carcinoma.Journal of endocrinological investigation · 2025Observational
- Racial and ethnic disparities in the risk of second primary malignancies in differentiated thyroid cancer patients: a population-based study.Endocrine · 2025Article
- Radiofrequency Ablation for Locoregional Structural Incomplete Response in Differentiated Thyroid Cancer: Initial Experience in Greece.Biomedicines · 2025Article
- Oldie but Goldie: The Fundamental Role of Radioiodine in the Management of Thyroid Cancer.Journal of clinical medicine · 2024Article
- Follow-up strategy of radiofrequency ablation for papillary thyroid microcarcinoma: defining a response-to-ablation system.European radiology · 2024Article
- Selective inhibition of DNA ligase IV provides additional efficacy to the treatment of anaplastic thyroid cancer.Frontiers in oncology · 2024Article
- Hearing the Voices of Australian Thyroid Cancer Survivors: Qualitative Thematic Analysis of Semistructured Interviews Identifies Unmet Support Needs.Thyroid : official journal of the American Thyroid Association · 2023Article
- Current patterns of care in low-risk thyroid cancer-A national cross-sectional survey of Australian thyroid clinicians.Endocrinology, diabetes & metabolism · 2023Article
- Risk assessment of cytologically indeterminate thyroid nodules with integrated molecular testing and repeat biopsy: a surgical decision-oriented tool.World journal of surgical oncology · 2023Article
- Knowledge, attitude, and practice towards thyroid nodules and cancer among patients: a cross-sectional study.Frontiers in public health · 2023Article
- Patient decision aids for patients with differentiated thyroid carcinoma: development process and alpha and beta testing.Frontiers in endocrinology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment paradigm for thyroid cancer has shifted from a one-size-fits-all approach to more personalized protocols that range from active surveillance to total thyroidectomy followed by radioiodine remnant ablation. Accurate surveillance tools are available, but follow-up protocols vary widely between centres and clinicians, owing to the lack of clear, straightforward recommendations on the instruments and assessment schedule that health-care professionals should adopt. For most patients (that is, those who have had an excellent response to the initial treatment and have a low or intermediate risk of tumour recurrence), an infrequent assessment schedule is sufficient (such as a yearly determination of serum levels of TSH and thyroglobulin). Select patients will benefit from second-line imaging and more frequent assessments. This Review discusses the strengths and weaknesses of the surveillance tools and follow-up strategies that clinicians use as a function of the initial treatment and each patient's risk of recurrence.
Indexed as
Identifiers
30069030What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.